Affimed (NASDAQ:AFMD) Shares Down 7.1%

Shares of Affimed NV (NASDAQ:AFMD) traded down 7.1% during trading on Thursday . The company traded as low as $2.28 and last traded at $2.34, 1,392,100 shares traded hands during mid-day trading. An increase of 167% from the average session volume of 521,384 shares. The stock had previously closed at $2.52.

A number of equities analysts have commented on the stock. ValuEngine raised shares of Affimed from a “sell” rating to a “hold” rating in a research note on Wednesday, August 28th. Zacks Investment Research cut shares of Affimed from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $6.36.

The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.47 and a current ratio of 3.48. The firm has a market cap of $162.21 million, a PE ratio of -6.37 and a beta of 2.91. The stock’s 50 day simple moving average is $2.87 and its 200 day simple moving average is $3.01.

A number of hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. purchased a new position in Affimed in the 3rd quarter worth approximately $1,051,000. California Public Employees Retirement System grew its stake in Affimed by 5.8% in the 3rd quarter. California Public Employees Retirement System now owns 185,100 shares of the biopharmaceutical company’s stock worth $544,000 after buying an additional 10,100 shares in the last quarter. Strs Ohio purchased a new position in Affimed in the 3rd quarter worth approximately $61,000. Meeder Asset Management Inc. purchased a new position in Affimed in the 3rd quarter worth approximately $47,000. Finally, Mackenzie Financial Corp purchased a new position in Affimed in the 2nd quarter worth approximately $47,000. 51.58% of the stock is owned by institutional investors and hedge funds.

About Affimed (NASDAQ:AFMD)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Further Reading: Why do companies issue stock splits?

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.